A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Exclusion Criteria

• - Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational, or hormonal therapy for treatment of lymphoma within 28 days prior to treatment;
• - Exposure to bendamustine within the 180 days before study enrollment
• - Prior autologous or allogeneic stem cell transplantation (SCT);
• - Clinically significant abnormality on electrocardiogram (ECG) as determined by the treating physician or medical monitor;
• - History of other invasive malignancy within 5 years except for localized/in situ carcinomas;
• - Evidence of active infection, Confirmed current central nervous system involvement by leukemia or lymphoma;